Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers.
List view / Grid view
Filter the results
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
A collapsible basket technology has been developed to significantly accelerate the analysis process when scientists are developing new medicines.
The model was tested on a panel of drugs that are both still on the market or have been recalled due to adverse effects and was able to show their toxicity.
New technology is for the first time enabling scientists to analyse the individual behaviour of millions of different cells living inside lab-grown tumours, which could lead to new personalised cancer treatments.
More effective drugs could be developed due to a new technique that has allowed scientists to decipher how millions of individual cells are communicating with each other on miniature tumours grown in a lab.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
Scientists have produced hundreds of organoids which they say could be produced on a large-scale as a low-cost tissue model to help research and test new medulloblastoma therapies.
Researchers have used stem cells, CRISPR and gene sequencing technology to create the basis of a new brain cancer model that could offer opportunities for drug discovery.
Drug Target Review explores the latest applications of stem cells in modelling disease, drug production and the most recent steps in regenerative medicine provided by research.
A collaboration between Elsevier and the FDA will present an algorithm for the accurate prediction of drug-induced liver injury. Drug Target Review investigates the benefits this toxicology project will bring to the drug discovery industry.
A new process for producing organoids allows researchers to explore intestinal epithelium in isolation and could allow for the development of improved targeted treatments of diseases.
Lab-grown brain organoids from patients’ glioblastomas could be useful models to rapidly test and identify effective personalised treatments, find researchers.
Researchers have found that a type of T cell, called a Tr1 cell, could work as a therapeutic strategy for inflammatory bowel disease in children.